Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: blommestein hm. Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Pharmacoeconomics. 2017. PMID: 28656543 Free PMC article. Review.
Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA. Franken MG, et al. Among authors: blommestein hm. Value Health. 2014 Mar;17(2):245-53. doi: 10.1016/j.jval.2013.12.009. Value Health. 2014. PMID: 24636383 Free article. Clinical Trial.
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ. Blommestein HM, et al. Pharmacoeconomics. 2016 Jan;34(1):23-31. doi: 10.1007/s40273-015-0318-3. Pharmacoeconomics. 2016. PMID: 26314282 Free PMC article.
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S, Blommestein HM, Redekop WK, Sleijfer S, Kiemeney LALM, Oosterwijk E, Uyl-de Groot CA. De Groot S, et al. Among authors: blommestein hm. PLoS One. 2017 May 22;12(5):e0177364. doi: 10.1371/journal.pone.0177364. eCollection 2017. PLoS One. 2017. PMID: 28531203 Free PMC article.
45 results